200
Views
448
CrossRef citations to date
0
Altmetric
Article

Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1

, , , &
Pages 7381-7393 | Received 14 Mar 2007, Accepted 24 Aug 2007, Published online: 27 Mar 2023

REFERENCES

  • Adhikary, S., and M. Eilers. 2005. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6:635–645.
  • Ashrafian, H. 2006. Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis. Lancet 367:618–621.
  • Baudino, T. A., C. McKay, H. Pendeville-Samain, J. A. Nilsson, K. H. Maclean, E. L. White, A. C. Davis, J. N. Ihle, and J. L. Cleveland. 2002. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16:2530–2543.
  • Berra, E., E. Benizri, A. Ginouves, V. Volmat, D. Roux, and J. Pouyssegur. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22:4082–4090.
  • Bonnet, S., S. L. Archer, J. Allalunis-Turner, A. Haromy, C. Beaulieu, R. Thompson, C. T. Lee, G. D. Lopaschuk, L. Puttagunta, G. Harry, K. Hashimoto, C. J. Porter, M. A. Andrade, B. Thebaud, and E. D. Michelakis. 2007. A mitochondria-k(+) channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51.
  • Brahimi-Horn, M. C., J. Chiche, and J. Pouyssegur. 2007. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19:223–229.
  • Bui, T., and C. B. Thompson. 2006. Cancer's sweet tooth. Cancer Cell 9:419–420.
  • Cole, M. D., and S. B. McMahon. 1999. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18:2916–2924.
  • Corn, P. G., M. S. Ricci, K. A. Scata, A. M. Arsham, M. C. Simon, D. T. Dicker, and W. S. El-Deiry. 2005. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol. Ther. 4:1285–1294.
  • Covello, K. L., J. Kehler, H. Yu, J. D. Gordan, A. M. Arsham, C. J. Hu, P. A. Labosky, M. C. Simon, and B. Keith. 2006. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20:557–570.
  • Covello, K. L., M. C. Simon, and B. Keith. 2005. Targeted replacement of hypoxia-inducible factor-1α by a hypoxia-inducible factor-2α knock-in allele promotes tumor growth. Cancer Res. 65:2277–2286.
  • Dang, C. V. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19:1–11.
  • Danial, N. N., C. F. Gramm, L. Scorrano, C. Y. Zhang, S. Krauss, A. M. Ranger, S. R. Datta, M. E. Greenberg, L. J. Licklider, B. B. Lowell, S. P. Gygi, and S. J. Korsmeyer. 2003. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 424:952–956.
  • Eisenman, R. N. 2001. Deconstructing myc. Genes Dev. 15:2023–2030.
  • Fantin, V. R., J. St.-Pierre, and P. Leder. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434.
  • Forsythe, J. A., B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, and G. L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604–4613.
  • Gao, P., H. Zhang, R. Dinavahi, L. Feng, Y. Xiang, V. Raman, Z. Bhujwalla, D. W. Felsher, L. Cheng, J. Pevsner, L. A. Lee, G. L. Semenza, and C. V. Dang. 2007. HIF-dependent anti-tumorigenic effect of anti-oxidants in vivo. Cancer Cell 12:230–238.
  • Gardner, L. B., Q. Li, M. S. Park, W. M. Flanagan, G. L. Semenza, and C. V. Dang. 2001. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276:7919–7926.
  • Gatenby, R. A., and R. J. Gillies. 2004. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4:891–899.
  • Giaccia, A., B. G. Siim, and R. S. Johnson. 2003. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2:803–811.
  • Giaccia, A. J., M. C. Simon, and R. Johnson. 2004. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 18:2183–2194.
  • Goda, N., H. E. Ryan, B. Khadivi, W. McNulty, R. C. Rickert, and R. S. Johnson. 2003. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23:359–369.
  • Golshani-Hebroni, S. G., and S. P. Bessman. 1997. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J. Bioenerg. Biomembr. 29:331–338.
  • Gordan, J. D., J. A. Bertout, C. J. Hu, J. A. Diehl, and M. C. Simon. 2007. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11:335–347.
  • Gordan, J. D., and M. C. Simon. 2007. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr. Opin. Genet. Dev. 17:71–77.
  • Gottlob, K., N. Majewski, S. Kennedy, E. Kandel, R. B. Robey, and N. Hay. 2001. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15:1406–1418.
  • Grandori, C., and R. N. Eisenman. 1997. Myc target genes. Trends Biochem. Sci. 22:177–181.
  • Hanahan, D., and R. A. Weinberg. 2000. The hallmarks of cancer. Cell 100:57–70.
  • Holness, M. J., and M. C. Sugden. 2003. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem. Soc. Trans. 31:1143–1151.
  • Hon, W. C., M. I. Wilson, K. Harlos, T. D. Claridge, C. J. Schofield, C. W. Pugh, P. H. Maxwell, P. J. Ratcliffe, D. I. Stuart, and E. Y. Jones. 2002. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 417:975–978.
  • Hu, C. J., L. Y. Wang, L. A. Chodosh, B. Keith, and M. C. Simon. 2003. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 23:9361–9374.
  • Hueber, A. O., and G. I. Evan. 1998. Traps to catch unwary oncogenes. Trends Genet. 14:364–367.
  • Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, and W. G. Kaelin, Jr. 2001. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468.
  • Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472.
  • Kelly, B. D., S. F. Hackett, K. Hirota, Y. Oshima, Z. Cai, S. Berg-Dixon, A. Rowan, Z. Yan, P. A. Campochiaro, and G. L. Semenza. 2003. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93:1074–1081.
  • Kim, J. W., and C. V. Dang. 2006. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66:8927–8930.
  • Kim, J. W., I. Tchernyshyov, G. L. Semenza, and C. V. Dang. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3:177–185.
  • Kim, J. W., K. I. Zeller, Y. Wang, A. G. Jegga, B. J. Aronow, K. A. O'Donnell, and C. V. Dang. 2004. Evaluation of Myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol. Cell. Biol. 24:5923–5936.
  • Kim, W. Y., M. Safran, M. R. Buckley, B. L. Ebert, J. Glickman, M. Bosenberg, M. Regan, and W. G. Kaelin, Jr. 2006. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J. 25:4650–4662.
  • Knies-Bamforth, U. E., S. B. Fox, R. Poulsom, G. I. Evan, and A. L. Harris. 2004. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res. 64:6563–6570.
  • Kondo, K., J. Klco, E. Nakamura, M. Lechpammer, and W. G. Kaelin, Jr. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237–246.
  • Koshiji, M., and L. E. Huang. 2004. Dynamic balancing of the dual nature of HIF-1α for cell survival. Cell Cycle 3:853–854.
  • Koshiji, M., Y. Kageyama, E. A. Pete, I. Horikawa, J. C. Barrett, and L. E. Huang. 2004. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23:1949–1956.
  • Koshiji, M., K. K. To, S. Hammer, K. Kumamoto, A. L. Harris, P. Modrich, and L. E. Huang. 2005. HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol. Cell 17:793–803.
  • Krishnamachary, B., D. Zagzag, H. Nagasawa, K. Rainey, H. Okuyama, J. H. Baek, and G. L. Semenza. 2006. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66:2725–2731.
  • Li, F., Y. Wang, K. I. Zeller, J. J. Potter, D. R. Wonsey, K. A. O'Donnell, J. W. Kim, J. T. Yustein, L. A. Lee, and C. V. Dang. 2005. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25:6225–6234.
  • Li, Z., S. Van Calcar, C. Qu, W. K. Cavenee, M. Q. Zhang, and B. Ren. 2003. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc. Natl. Acad. Sci. USA 100:8164–8169.
  • Liu, L., T. P. Cash, R. G. Jones, B. Keith, C. B. Thompson, and M. C. Simon. 2006. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21:521–531.
  • Majewski, N., V. Nogueira, R. B. Robey, and N. Hay. 2004. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell. Biol. 24:730–740.
  • Maltepe, E., and M. C. Simon. 1998. Oxygen, genes, and development: an analysis of the role of hypoxic gene regulation during murine vascular development. J. Mol. Med. 76:391–401.
  • Maranchie, J. K., J. R. Vasselli, J. Riss, J. S. Bonifacino, W. M. Linehan, and R. D. Klausner. 2002. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247–255.
  • Masson, N., C. Willam, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:5197–5206.
  • Mateyak, M. K., A. J. Obaya, S. Adachi, and J. M. Sedivy. 1997. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8:1039–1048.
  • Mathupala, S. P., A. Rempel, and P. L. Pedersen. 2001. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276:43407–43412.
  • Mazure, N. M., C. Chauvet, B. Bois-Joyeux, M. A. Bernard, H. Nacer-Cherif, and J. L. Danan. 2002. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res. 62:1158–1165.
  • Min, J. H., H. Yang, M. Ivan, F. Gertler, W. G. Kaelin, Jr., and N. P. Pavletich. 2002. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296:1886–1889.
  • Nesbit, C. E., J. M. Tersak, and E. V. Prochownik. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18:3004–3016.
  • Orian, A., S. S. Grewal, P. S. Knoepfler, B. A. Edgar, S. M. Parkhurst, and R. N. Eisenman. 2005. Genomic binding and transcriptional regulation by the Drosophila Myc and Mnt transcription factors. Cold Spring Harbor Symp. Quant. Biol. 70:299–307.
  • Osthus, R. C., H. Shim, S. Kim, Q. Li, R. Reddy, M. Mukherjee, Y. Xu, D. Wonsey, L. A. Lee, and C. V. Dang. 2000. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 275:21797–21800.
  • Pajic, A., D. Spitkovsky, B. Christoph, B. Kempkes, M. Schuhmacher, M. S. Staege, M. Brielmeier, J. Ellwart, F. Kohlhuber, G. W. Bornkamm, A. Polack, and D. Eick. 2000. Cell cycle activation by c-myc in a Burkitt lymphoma model cell line. Int. J. Cancer 87:787–793.
  • Papandreou, I., R. A. Cairns, L. Fontana, A. L. Lim, and N. C. Denko. 2006. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3:187–197.
  • Parry, D. M., and P. L. Pedersen. 1983. Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location. J. Biol. Chem. 258:10904–10912.
  • Pastorino, J. G., and J. B. Hoek. 2003. Hexokinase II: the integration of energy metabolism and control of apoptosis. Curr. Med. Chem. 10:1535–1551.
  • Pastorino, J. G., N. Shulga, and J. B. Hoek. 2002. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem. 277:7610–7618.
  • Pelengaris, S., M. Khan, and G. Evan. 2002. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2:764–776.
  • Ponzielli, R., S. Katz, D. Barsyte-Lovejoy, and L. Z. Penn. 2005. Cancer therapeutics: targeting the dark side of Myc. Eur. J. Cancer 41:2485–2501.
  • Pugh, C. W., and P. J. Ratcliffe. 2003. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9:677–684.
  • Rathmell, J. C., C. J. Fox, D. R. Plas, P. S. Hammerman, R. M. Cinalli, and C. B. Thompson. 2003. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23:7315–7328.
  • Ryan, H. E., J. Lo, and R. S. Johnson. 1998. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:3005–3015.
  • Schofield, C. J., and P. J. Ratcliffe. 2004. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5:343–354.
  • Schuhmacher, M., M. S. Staege, A. Pajic, A. Polack, U. H. Weidle, G. W. Bornkamm, D. Eick, and F. Kohlhuber. 1999. Control of cell growth by c-Myc in the absence of cell division. Curr. Biol. 9:1255–1258.
  • Semenza, G. L. 2002. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8:S62–S67.
  • Semenza, G. L. 2001. HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107:1–3.
  • Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721–732.
  • Semenza, G. L., P. H. Roth, H. M. Fang, and G. L. Wang. 1994. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269:23757–23763.
  • Shaw, R. J. 2006. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18:598–608.
  • Shchors, K., E. Shchors, F. Rostker, E. R. Lawlor, L. Brown-Swigart, and G. I. Evan. 2006. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β. Genes Dev. 20:2527–2538.
  • Shim, H., C. Dolde, B. C. Lewis, C. S. Wu, G. Dang, R. A. Jungmann, R. Dalla-Favera, and C. V. Dang. 1997. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 94:6658–6663.
  • Tian, H., S. L. McKnight, and D. W. Russell. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:72–82.
  • To, K. K., M. Koshiji, S. Hammer, and L. E. Huang. 2005. Genetic instability: the dark side of the hypoxic response. Cell Cycle 4:881–882.
  • Wang, G. L., and G. L. Semenza. 1993. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 90:4304–4308.
  • Warburg, O. 1956. On respiratory impairment in cancer cells. Science 124:269–270.
  • Warburg, O. 1956. On the origin of cancer cells. Science 123:309–314.
  • Zeller, K. I., X. Zhao, C. W. Lee, K. P. Chiu, F. Yao, J. T. Yustein, H. S. Ooi, Y. L. Orlov, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, V. A. Kuznetsov, W. K. Sung, Y. Ruan, C. V. Dang, and C. L. Wei. 2006. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc. Natl. Acad. Sci. USA 103:17834–17839.
  • Zhang, H., P. Gao, R. Fukuda, G. Kumar, B. Krishnamachary, K. I. Zeller, C. V. Dang, and G. L. Semenza. 2007. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11:407–420.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.